Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 10 Myeloid 10 Lymphoid 8 Classical hematology 4 Plasma cell 2 Genitourinary 2 Tumor-Agnostic 1 Thoracic 1 Dermatologic 1

Conditions

Thymoma 1 Thymic epithelial tumor 1

Interventions

Carboplatin 544 Pemetrexed 394 pembrolizumab 373 Cisplatin 358 Paclitaxel 285 Docetaxel 240 Gemcitabine 168 Nivolumab 158 Erlotinib Hydrochloride 147 Bevacizumab 114 atezolizumab 104 osimertinib 99 durvalumab 92 Etoposide 90 Gefitinib 68 130-nm albumin-bound paclitaxel 65 Cetuximab 64 Ipilimumab 60 Drug Therapy 51 Topotecan 48 Injections 44 tislelizumab 41 Afatinib 41 Cyclophosphamide 39 Albumin-Bound Paclitaxel 37 Vinorelbine 36 Crizotinib 34 cemiplimab 31 icotinib 26 Radiotherapy 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × AP 1903 reagent × Thoracic × Clear all

NCT07598955 2026-05-20

SELECT-NK-THYM

Beijing Biotech

Phase 1/2 Recruiting

Thymic epithelial tumor, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡